secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2026-07-06T11:11:45+00:00
Accession:  0001193125-26-295539
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd receives FDA notice of PEMGARDA EUA termination effective June 29, 2027; plans to pursue BLA approval
--------------------------------------------------------------------------------

- FDA sent Invivyd Notice of Termination for PEMGARDA EUA, effective June 29, 2027, following HHS termination of COVID-19 EUA declaration.
- PEMGARDA (pemivibart) authorized since March 2024 for COVID-19 pre-exposure prophylaxis in immunocompromised individuals.
- Invivyd intends to pursue Biologics License Application (BLA) for full FDA approval, citing clinical and post-authorization data.
- Company is in active dialogue with FDA on next steps; HHS has not provided specific written advice on approval pathway.
- Chairman Marc Elia states PEMGARDA has sufficient data for BLA submission and approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312526295539/0001193125-26-295539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312526295539/ivvd-20260706.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-295539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer